{
    "clinical_study": {
        "@rank": "73797", 
        "arm_group": {
            "arm_group_label": "Patients with prescription for low dose ASA (75-300 mg/day)"
        }, 
        "brief_summary": {
            "textblock": "This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained.\n      The aims of the post hoc analyses  are:\n\n      To estimate the incidence of uncomplicated peptic ulcer (UPU) in a cohort of low-dose ASA\n      for secondary prevention of vascular disease and the relative risk of UPU associated with\n      use and discontinuation of use of low dose ASA.\n\n      To estimate the effect of proton pump inhibitors (PPI) on the occurrence of UPU among users\n      of low-dose ASA for secondary prevention of vascular disease To evaluate the effect of other\n      risk factors on the occurrence of UPU among users of low-dose ASA for secondary prevention\n      of vascular disease."
        }, 
        "brief_title": "The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Uncomplicated Peptic Ulcer", 
        "condition_browse": {
            "mesh_term": [
                "Peptic Ulcer", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "The risk of uncomplicated peptic ulcer in a cohort of secondary prevention aspirin users"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients aged 50-84 years in 2000-2007 with a first prescription of low dose ASA ( see\n        study population description)\n\n        Exclusion Criteria:\n\n        - Patients aged below age 50 and 85 years and above ( see study population description)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "50 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients aged 50-84 yrs who had a first prescription of low-dose ASA (75-300mg/day) for\n        secondary cardiovascular or cerebrovascular prevention in 2000-2007 in The Health\n        Improvement Network database in the UK.  Patients had to be enrolled with their PCP\n        (Primary Care Physician) for at least 2 years and  have a health contact in the year\n        prior. Patients with use of aspirin ever recorded in the database before start of\n        follow-up as well as patient with cancer or alcohol abuse were excluded. Individuals were\n        followed up until the earliest occurrence of one of the following endpoints; first\n        recorded diagnosis of uncomplicated peptic ulcer, canser, alcohol abuse or alcohol related\n        disease, reaching the age of 85 years old, date of last practice data collection, death or\n        end of follow-up ( 30 September 2011).Patient records were manually reviewed to validate\n        cases."
            }
        }, 
        "enrollment": {
            "#text": "39000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814943", 
            "org_study_id": "D5040N00007"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Uncomplicated peptic ulcer", 
            "Acid-suppressing drugs", 
            "Epidemiology"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users", 
        "overall_official": {
            "affiliation": "CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research )", 
            "last_name": "Luis A Garcia Rodriguez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Oversight authority: Not applicable", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence rates of uncomplicated peptic ulcer in a cohort of secondary prevention aspirin users", 
                "safety_issue": "No", 
                "time_frame": "From 1 January 2000 till 30 September 2011, an expected average of 6 years."
            }, 
            {
                "measure": "Risk (hazard ratio) of developing uncomplicated peptic ulcer in a cohort of secondary prevention aspirin users", 
                "safety_issue": "No", 
                "time_frame": "From 1 Januart 2000 till 30 September 2011, an expected average of 6 years"
            }
        ], 
        "reference": [
            {
                "PMID": "21811460", 
                "citation": "Cea Soriano L, Rodr\u00edguez LA. Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol. 2010;1:126. doi: 10.3389/fphar.2010.00126. Epub 2010 Oct 14."
            }, 
            {
                "PMID": "21270415", 
                "citation": "Garc\u00eda Rodr\u00edguez LA, Cea Soriano L, Hill C, Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011 Feb 22;76(8):740-6. doi: 10.1212/WNL.0b013e31820d62b5. Epub 2011 Jan 26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814943"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}